相关实验视频

Updated: Jul 4, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

在巨细胞动脉炎中,IL-17通路作为点

Markus Zeisbrich¹, Jens Thiel^1,2, Nils Venhoff¹

¹Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Freiburg, Germany.

Frontiers in immunology

|February 1, 2024

概括

一种IL-17A抑制剂Secukinumab在治疗巨细胞动脉炎方面表现有前途. 这种针对性治疗可以为50岁以上的患者提供一种新的选择,解决大血管血管炎治疗的未满足需求.

科学领域:

免疫学免疫学免疫学
类风湿病学类风湿病学
血管生物学血管生物学

背景情况:

介素-17 (IL-17) 细胞因子网络与自身免疫和炎症性疾病有关.
像secukinumab这样的IL-17A抑制剂对牛皮,牛皮关节炎和轴性脊柱关节炎是有效的.
巨细胞动脉炎 (GCA) 是一种影响50岁以上个体的大血管血管炎,显示出IL-17和Th17细胞参与的证据.

研究的目的:

为了研究塞库金纽马布作为治疗巨细胞动脉炎的潜力.
评估secuquinumab在治疗GCA患者急性炎症方面的疗效.
评估secukinumab在患有GCA的老年患者群体中的安全性.

主要方法:

第二阶段原则证明研究 (TitAIN).
对secukinumab对GCA中的IL-17通路的影响的评估.
对用secukinumab治疗的GCA患者的临床结果和安全性的评估.

主要成果:

来自TitAIN研究的初步结果表明,GCA中的secukinumab的前景是积极的.
塞库金纽马布在抑制GCA特征的急性炎症方面表现出潜在的潜力.
这项研究支持secukinumab作为一种潜在的葡萄糖皮质体储存剂GCA.

结论:

塞库金纽马布是巨细胞动脉炎的潜在新疗法选择.
用secokinumab准IL-17A可能会解决对GCA有效和安全治疗的需求.
需要进一步的研究来证实secukinumab在管理GCA中的作用,特别是在对当前治疗有禁忌的患者中.

关键词:

它们的IL-17和IL-17.在 Th-17 中.巨细胞动脉炎 (GCA)干燥的干燥的干燥血管炎是一种血管炎.

更多相关视频

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

Intracellular Staining and Flow Cytometry to Identify Lymphocyte Subsets within Murine Aorta, Kidney and Lymph Nodes in a Model of Hypertension

Intracellular Staining and Flow Cytometry to Identify Lymphocyte Subsets within Murine Aorta, Kidney and Lymph Nodes in a Model of Hypertension

Published on: January 28, 2017

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...